Skip to main content
Top
Published in: Abdominal Radiology 10/2023

Open Access 26-06-2023 | Rectal Cancer | Hollow Organ GI

Predicting response to chemoradiotherapy in rectal cancer via visual morphologic assessment and staging on baseline MRI: a multicenter and multireader study

Authors: Najim El Khababi, Regina G. H. Beets-Tan, Renaud Tissier, Max J. Lahaye, Monique Maas, Luís Curvo-Semedo, Raphaëla C. Dresen, Stephanie Nougaret, Geerard L. Beets, Doenja M. J. Lambregts, on behalf of the rectal MRI study group

Published in: Abdominal Radiology | Issue 10/2023

Login to get access

Abstract

Purpose

Pre-treatment knowledge of the anticipated response of rectal tumors to neoadjuvant chemoradiotherapy (CRT) could help to further optimize the treatment. Van Griethuysen et al. proposed a visual 5-point confidence score to predict the likelihood of response on baseline MRI. Aim was to evaluate this score in a multicenter and multireader study setting and compare it to two simplified (4-point and 2-point) adaptations in terms of diagnostic performance, interobserver agreement (IOA), and reader preference.

Methods

Twenty-two radiologists from 14 countries (5 MRI-experts,17 general/abdominal radiologists) retrospectively reviewed 90 baseline MRIs to estimate if patients would likely achieve a (near-)complete response (nCR); first using the 5-point score by van Griethuysen (1=highly unlikely to 5=highly likely to achieve nCR), second using a 4-point adaptation (with 1-point each for high-risk T-stage, obvious mesorectal fascia invasion, nodal involvement, and extramural vascular invasion), and third using a 2-point score (unlikely/likely to achieve nCR). Diagnostic performance was calculated using ROC curves and IOA using Krippendorf’s alpha (α).

Results

Areas under the ROC curve to predict the likelihood of a nCR were similar for the three methods (0.71–0.74). IOA was higher for the 5- and 4-point scores (α=0.55 and 0.57 versus 0.46 for the 2-point score) with best results for the MRI-experts (α=0.64-0.65). Most readers (55%) favored the 4-point score.

Conclusions

Visual morphologic assessment and staging methods can predict neoadjuvant treatment response with moderate–good performance. Compared to a previously published confidence-based scoring system, study readers preferred a simplified 4-point risk score based on high-risk T-stage, MRF involvement, nodal involvement, and EMVI.

Graphical abstract

Appendix
Available only for authorised users
Literature
3.
go back to reference van der Valk MJM, Hilling DE, Bastiaannet E et al (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391(10139):2537-2545. https://doi.org/https://doi.org/10.1016/S0140-6736(18)31078-XCrossRefPubMed van der Valk MJM, Hilling DE, Bastiaannet E et al (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391(10139):2537-2545. https://​doi.​org/​https://​doi.​org/​10.​1016/​S0140-6736(18)31078-XCrossRefPubMed
4.
go back to reference Bach SP; STAR-TREC Collaborative (2022) Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches. Colorectal Dis 24(5):639-651. https://doi.org/https://doi.org/10.1111/codi.16056CrossRefPubMedPubMedCentral Bach SP; STAR-TREC Collaborative (2022) Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches. Colorectal Dis 24(5):639-651. https://​doi.​org/​https://​doi.​org/​10.​1111/​codi.​16056CrossRefPubMedPubMedCentral
17.
go back to reference van Griethuysen JJM, Lambregts DMJ, Trebeschi S et al (2020) Radiomics performs comparable to morphologic assessment by expert radiologists for prediction of response to neoadjuvant chemoradiotherapy on baseline staging MRI in rectal cancer. Abdom Radiol (NY) 45(3):632-643. https://doi.org/https://doi.org/10.1007/s00261-019-02321-8CrossRefPubMed van Griethuysen JJM, Lambregts DMJ, Trebeschi S et al (2020) Radiomics performs comparable to morphologic assessment by expert radiologists for prediction of response to neoadjuvant chemoradiotherapy on baseline staging MRI in rectal cancer. Abdom Radiol (NY) 45(3):632-643. https://​doi.​org/​https://​doi.​org/​10.​1007/​s00261-019-02321-8CrossRefPubMed
18.
go back to reference Beets-Tan RGH, Lambregts DMJ, Maas M et al (2018) Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting [published correction appears in Eur Radiol. 2018 Jan 10;:]. Eur Radiol 28(4):1465-1475. https://doi.org/10.1007/s00330-017-5026-2 Beets-Tan RGH, Lambregts DMJ, Maas M et al (2018) Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting [published correction appears in Eur Radiol. 2018 Jan 10;:]. Eur Radiol 28(4):1465-1475. https://​doi.​org/​10.​1007/​s00330-017-5026-2
32.
Metadata
Title
Predicting response to chemoradiotherapy in rectal cancer via visual morphologic assessment and staging on baseline MRI: a multicenter and multireader study
Authors
Najim El Khababi
Regina G. H. Beets-Tan
Renaud Tissier
Max J. Lahaye
Monique Maas
Luís Curvo-Semedo
Raphaëla C. Dresen
Stephanie Nougaret
Geerard L. Beets
Doenja M. J. Lambregts
on behalf of the rectal MRI study group
Publication date
26-06-2023
Publisher
Springer US
Published in
Abdominal Radiology / Issue 10/2023
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-023-03961-7

Other articles of this Issue 10/2023

Abdominal Radiology 10/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.